MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Oragenics, Inc. (OGEN) Makes A Significant Leap Forward In Effort To Produce Commercial Quantities Of Lead Lantibiotic 0 comments
    Feb 12, 2013 3:45 PM | about stocks: OGEN

    Earlier today, Oragenics announced that it has produced an exponential increase in the fermentation titer of the target compound MU1140 via an Exclusive Channel Collaboration (NYSE:ECC) with Intrexon Corporation, a synthetic biology company. Oragenics also discovered a promising new purification process for this product.

    This latest progress in the lab demonstrates an important advance towards the commercial production of Oragenics' lead lantibiotic, MU1140, and delivers an important step in validating the lantibiotics platform targeting infectious diseases. Oragenics and Intrexon have combined their efforts and expertise to produce a pipeline of new lantibiotics that have been shown to be active against essentially all Gram-positive pathogens, including vancomycin-resistant enterococci (VRE), Clostridium difficile, methicillin-resistant Staphylococcus aureus (MRSA), as well as multi-drug resistant strains of Mycobacterium tuberculosis.

    Dr. John N. Bonfiglio, Chief Executive Officer of Oragenics, stated, "The ability to manufacture MU1140 by fermentation was originally thought not to be commercially feasible due to low titers and difficulties in purification. The Oragenics-Intrexon ECC clearly shows that the application of specific expertise in these areas represents a breakthrough by developing a potentially viable commercial process for these important anti-infective agents."

    According to today's news release, Oragenics and Intrexon are also working to leverage Intrexon's genetic and cell engineering proficiencies to produce analogs of MU1140 and a pipeline of new lantibiotics. "We believe the newly developed process will provide for the first time, the necessary quantities of MU1140 to complete critical development activities," emphasized Dr. Bonfiglio.

    For more information on Orangenics and its peptide antibiotics, visit www.oragenics.com

    Sign up for "The Mission Report" at www.MissionIR.com

    Stocks: OGEN
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.